Enzo Biochem (NYSE:ENZ – Get Free Report) released its quarterly earnings data on Monday. The medical research company reported ($0.02) earnings per share for the quarter, Zacks reports. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.
Enzo Biochem Trading Down 4.7 %
Shares of NYSE ENZ opened at $0.47 on Tuesday. The firm’s 50-day moving average price is $0.57 and its 200-day moving average price is $0.87. Enzo Biochem has a 1-year low of $0.41 and a 1-year high of $1.30.
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of Enzo Biochem in a report on Saturday. They set a “hold” rating on the stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Articles
- Five stocks we like better than Enzo Biochem
- High Flyers: 3 Natural Gas Stocks for March 2022
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
- Health Care Stocks Explained: Why You Might Want to Invest
- ARK Innovation Fund Bets Big on Bitcoin—Will It Pay Off?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Can TikTok Stock Picks Really Make You Rich?
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.
